Does CD40 rs1883832 CT increase autoimmune thyroid risk?

The CD40 rs1883832 single-nucleotide polymorphism plays a critical role in tuning immune system costimulation and modulating susceptibility to autoimmune thyroid diseases.

Molecular mechanisms and signaling

• Translational modulation: Located at the -1 position of the Kozak translation initiation sequence of the CD40 gene, this polymorphism directly alters translation efficiency. The C allele facilitates high CD40 translation, whereas the T allele reduces it, positioning the heterozygous CT genotype as an intermediate-expression state.
• Downstream signaling: Cell-surface CD40 density directly dictates the magnitude of downstream TRAF-mediated NF-κB activation. The CT genotype quantitatively tunes downstream costimulatory pathways, B-cell activation, and class-switch recombination relative to the homozygous states.

Clinical and autoantibody associations

• Graves' disease susceptibility: The CT genotype is associated with intermediate susceptibility to Graves' disease, carrying an odds ratio (OR) of approximately 1.21 compared to the protective TT genotype, while offering a protective effect compared to the high-risk CC genotype.
• Disease specificity: Broad genetic analyses show no significant association between the rs1883832 variant and Hashimoto's thyroiditis, highlighting its specific involvement in Graves' disease pathogenesis.
• Autoantibody persistence: In patients with Graves' disease, carrying the C allele (both CC and CT genotypes) correlates with persistently elevated thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) autoantibodies, though this effect requires an active autoimmune environment and does not occur in healthy individuals.

Bottom line

• The CD40 rs1883832 CT genotype acts as an intermediate-expression phenotype that moderately increases susceptibility to Graves' disease (OR ≈ 1.21) and promotes persistent TPOAb and TgAb production within an active autoimmune context, but is not associated with Hashimoto's thyroiditis.